Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
What is your approach to evaluation in patients who present with erythromelalgia?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?
How do you approach work up for underlying rheumatologic disease in patients referred for chronic urticaria?
How do you counsel and manage joint pain after isotretinoin treatment?
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?
Have you seen drug induced SCLE from IL-17 inhibitors?
What is your approach to management of drug induced oral and cutaneous lichen planus associated with TNF inhibitors?
